ライフサイエンスコーパス: age-related maculopathy

1 tional Classification and Grading System for Age-Related Maculopathy.

2 Matrix expansion is an early change in age-related maculopathy.

3 apparent independent birth cohort effect on age-related maculopathy.

4 d 10.32 (95% CI: 0.83, 128.58) for exudative age-related maculopathy.

5 s in macular function observed in ageing and age-related maculopathy.

6 o basal linear deposit, which accumulates in age-related maculopathy.

7 of these agents alone and in combination on age-related maculopathy.

8 amin supplement use affects the incidence of age-related maculopathy.

9 elation between smoking and the incidence of age-related maculopathy.

10 idence of some lesions associated with early age-related maculopathy.

11 the International Classification System for Age-Related Maculopathy.

12 shed on the relation of cigarette smoking to age-related maculopathy, an important cause of blindness

13 found a strong positive association between age-related maculopathy and age, when comparing particip

14 ells could be involved in the development of age-related maculopathy and age-related macular degenera

15 Age-related maculopathy and atherosclerotic cardiovascul

16 attributable to unmeasured risk factors for age-related maculopathy and limitations of risk factor m

17 rding to the International Classification of Age-related Maculopathy and Macular Degeneration.

18 the International Classification System for age-related maculopathy and stratified using the Rotterd

19 These data indicate signs of age-related maculopathy are common in people 75 years of

20 hat strong family determinants of lesions of age-related maculopathy are likely, less so for age-rela

21 ltivitamins, large reductions in the risk of age-related maculopathy are unlikely.

22 m to photographic evidence of early and late age-related maculopathy (ARM) among persons over age 40

23 participating in ARMA, a study of aging and age-related maculopathy (ARM) ancillary to the Health, A

24 h AMD were classified into two groups: early age-related maculopathy (ARM) and neovascular AMD.

25 roteinase 2 (MMP2) genes are associated with age-related maculopathy (ARM) in older women.

26 l consumption and the long-term incidence of age-related maculopathy (ARM) in people in the Beaver Da

27 Age-related maculopathy (ARM) is a leading cause of visu

28 Age-related maculopathy (ARM) is a leading cause of visu

29 Age-related macular degeneration or age-related maculopathy (ARM) is a major public health i

30 Age-related maculopathy (ARM) is an important cause of v

31 Age-related maculopathy (ARM) is one of the most common

32 The pathogenesis of age-related maculopathy (ARM) is related to adverse vasc

33 and zinc and the 5-year incidence of early, age-related maculopathy (ARM) were investigated in a pop

34 Macular drusen are hallmarks of age-related maculopathy (ARM), but these focal extracell

35 Age-related maculopathy (ARM), or age-related macular de

36 Several dietary factors have been linked to age-related maculopathy (ARM), the early form of age-rel

37 de linkage studies of families affected with age-related maculopathy (ARM), we previously identified

38 ort barrier in aging and lesion formation in age-related maculopathy (ARM).

39 ) photostress test and the focal cone ERG in age-related maculopathy (ARM).

40 racellular lesions associated with aging and age-related maculopathy (ARM).

41 alth Study I who did not have a diagnosis of age-related maculopathy at baseline (1982).

42 rs, may explain changes in the prevalence of age-related maculopathy by age.

43 ere determined by using a modified Wisconsin Age-Related Maculopathy Grading Scale (a 6-level scale:

44 presence of AMD lesions using the Wisconsin Age-Related Maculopathy grading scheme.

45 c data were graded according to the Clinical Age-Related Maculopathy Grading System (CARMS) as grade

46 ographs that were graded using the Wisconsin Age-related Maculopathy Grading System (n = 5).

47 subject and were graded using the Wisconsin Age-Related Maculopathy Grading System (WARMGS).

48 tinal photographs according to the Wisconsin Age-Related Maculopathy Grading System and Airlie House

49 ion of AMD (assessed by use of the Wisconsin Age-Related Maculopathy Grading System on retinal photog

50 The Wisconsin Age-Related Maculopathy Grading System was used to grade

51 ication, a modified version of the Wisconsin age-related maculopathy grading system, and AMD genetic

52 egeneration was assessed using the Wisconsin Age-related Maculopathy Grading System, and severity was

53 dised grading classifications (the Wisconsin age-related maculopathy grading system, the internationa

54 color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.

55 graphic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System.

56 graphic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System.

57 tinal photographs according to the Wisconsin Age-Related Maculopathy Grading System.

58 tinal photographs according to the Wisconsin Age-Related Maculopathy Grading System.

59 or ARM using a modification of the Wisconsin Age-Related Maculopathy Grading System.

60 undus photographs according to the Wisconsin Age-Related Maculopathy grading system.

61 ages were graded for AMD using the Wisconsin Age-related Maculopathy Grading System.

62 e volunteers was determined by the Wisconsin Age-Related Maculopathy Grading System.

63 hotographs graded using a modified Wisconsin Age-Related Maculopathy Grading System.

64 color fundus photographs using the Wisconsin Age-related Maculopathy Grading System.

65 color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.

66 e number of people in the United States with age-related maculopathy is increasing in recent years be

67 cigarettes were more likely to develop early age-related maculopathy (odds ratio (OR) per 10 pack-yea

68 oretinopathy, subretinal neovascularization, age-related maculopathy, optic nerve disorders, and nerv

69 sible but nonsignificant 13% reduced risk of age-related maculopathy (relative risk = 0.87, 95 percen

70 Patients with age-related maculopathy sensitivity 2 (ARMS2) risk allel

71 es into categories using a modified Clinical Age-Related Maculopathy Staging (CARMS) system.

72 Presence of AMD as defined by the Clinical Age-Related Maculopathy Staging system based on color fu

73 is of AMD was made according to the Clinical Age-Related Maculopathy Staging System.

74 elated Maculopathy Study (2001-2002) and the Age-Related Maculopathy Statin Study (2004-2006).

75 Age-related maculopathy status was determined by grading

76 individuals (346 sib pairs) from the Family Age Related Maculopathy Study (FARMS).

77 rom 2 studies: the Cardiovascular Health and Age-Related Maculopathy Study (2001-2002) and the Age-Re

78 ta from a previous GWS on AMD (FARMS [Family Age-Related Maculopathy Study]sample of 34 extended fami

79 ypes Complement Factor H (CFH) RS1061170 and Age Related Maculopathy Susceptibility 2 (ARMS2) RS37939

80 genotyped for 2 alleles associated with AMD, age-related maculopathy susceptibility 2 (ARMS2) and com

81 r age, sex, body mass index, smoking status, age-related maculopathy susceptibility 2 (ARMS2) and com

82 some 10q26 (Chr10) locus, which contains the age-related maculopathy susceptibility 2 (ARMS2) and hig

83 gous carriers of the A69S risk allele in the age-related maculopathy susceptibility 2 (ARMS2) gene (P

84 indel, del443/ins54), which are found in the age-related maculopathy susceptibility 2 (ARMS2) gene, a

85 alleles of the complement factor H (CFH) or age-related maculopathy susceptibility 2 (ARMS2) genes,

86 rphisms in the complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genes.

87 Age-related maculopathy susceptibility 2 (ARMS2) is cons

88 the complement factor H (CFH)-rs1061170 and age-related maculopathy susceptibility 2 (ARMS2)-rs10490

89 or H (CFH):rs570618-T, CFH:rs10922109-C, and Age-Related Maculopathy Susceptibility 2 (ARMS2)/High-Te

90 ctions with complement factor H (rs1061170), age-related maculopathy susceptibility 2 (rs10490924), c

91 st prevalent amino acid substitutions in the age-related maculopathy susceptibility 2 gene linked to

92 4 risk alleles in a joint effect analysis of Age-Related Maculopathy Susceptibility 2 rs10490924 and

93 th the well-established AMD risk loci ARMS2 (age-related maculopathy susceptibility 2)-HTRA1 (HtrA se

94 en loci in 7 AMD genes [complement factor H, age-related maculopathy susceptibility 2/high-temperatur

95 loci in 7 genes [complement factor H (CFH), age-related maculopathy susceptibility 2/high-temperatur

96 02H in complement factor H (CFH) and A69S in age-related maculopathy susceptibility locus 2 (ARMS2).

97 n complement Factor H gene (CFH) p.Y402H and age-related maculopathy susceptibility protein 2 gene (A

98 We have conducted two genome-wide scans for age-related maculopathy using the Center for Inherited D

99 stics of drusen and other lesions typical of age-related maculopathy were determined by grading stere

100 Lesions typical of age-related maculopathy were determined by masked gradin

101 Lesions associated with early age-related maculopathy were distributed in specific pat

102 Various lesions associated with early age-related maculopathy were located in specific pattern

103 eas pigmentary abnormalities associated with age-related maculopathy were more prevalent in the super

104 cross different age groups, except for early age-related maculopathy, where older age increased the a

105 follow-up, a total of 279 incident cases of age-related maculopathy with vision loss to 20/30 or wor